New platform aims to predict which cancer treatments will work
NCT ID NCT06349642
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participants will provide samples, and the results will help develop better tools for personalized cancer care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Arizona
RECRUITINGPhoenix, Arizona, 85054, United States
Contact Email: •••••@•••••
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224, United States
Contact Email: •••••@•••••
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?